A new collaboration aims to accelerate the development of large-molecule therapeutics capable of entering the brain to treat neurological conditions,…
Articles by Andrea Lobo
Zambon Biotech has dosed the first patient in its clinical trial testing Crexont (IPX203) — an extended-release formulation…
GT-02287, an oral therapy being developed by Gain Therapeutics, can increase glucocerebrosidase (GCase) enzyme activity in the brains of…
The Michael J. Fox Foundation (MJFF) has awarded a $1 million research grant to MODAG to advance new…
Biotechnology company Ophidion is teaming up with Neuronasal, a clinical-stage company focused on nose-to-brain delivery of therapies for central…
Kenai Therapeutics said the first patient has been dosed in a Phase 1 clinical trial testing the safety and efficacy…
Three research teams investigating five high-potential targets for new Parkinson’s disease therapies received initial funding under a multi-year initiative…
Solengepras, an experimental once-daily pill for Parkinson’s disease, significantly reduces the time patients spend with re-emerging…
Dysfunctional nerve cells in the brain’s motor command center may be driving the rigid brain wave patterns associated with…
People with Parkinson’s disease exhibit an interplay between the loss of dopamine-producing neurons and overall nerve…